. Author manuscript; available in PMC: 2022 Jan 6.

Published in final edited form as: Cancer Discov. 2021 Jun 14;11(10):2544–2563. doi: 10.1158/2159-8290.CD-20-0872

Table 1.

PKA Inhibitors tested

Drug	K_i PKA	K_i against other kinases	EC₅₀ FLC	EC₅₀ PHH
H89	48nM	PKG 480nM	FLC1 5.82μM FLC2 23.88μM FLC3 18.17μM FLC4 20.94μM FLC5 9.49μM	41.5 μM
KT5720	60nM	PKG/PKC >2μM	FLC1 1.61μM FLC2 2.14μM FLC3 2.71μM FLC4 1.48μM FLC5 3.87μM	>10 μM
A-674563	16nM	Akt1 11nM CDK2 46nM GSK-3β 110nM ERK2 260nM PKCδ 360nM RSK2 580nM	FLC1 0.34μM FLC2 0.7μM FLC3 0.88μM FLC4 0.16μM FLC5 3.45μM	3.45μM
Capivasertib (AZD5363)	7nM	Akt1 3nM Akt2 8nM Akt3 8nM	FLC1 2.98μM FLC2 3.85μM FLC3 5.15μM FLC4 2.09μM FLC5 12.6μM	>10 μM
AT13148	3nM	Akt1 38nM Akt2 402nM Akt3 50nM p70s6k 8nM Rock1 6nM Rock2 4nM	FLC1 0.039μM FLC2 6.14μM FLC3 0.59μM FLC4 4.29μM FLC5 0.096μM	4.05 μM
Uprosertib (GSK2141795)	2 nM	Akt1 180nM Akt2 328nM Akt3 38nM	FLC1 0.049μM FLC2 5.039 μM FLC3 0.87 μM FLC4 0.91 μM FLC5 1.72 μM	> 10 μM